+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Antipsychotic Drugs Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • PDF Icon

    Report

  • 193 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5753806
The Global Antipsychotic Drugs Market is estimated to be USD 17.02 Bn in 2023 and is expected to reach USD 30.12 Bn by 2028 growing at a CAGR of 12.09%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Antipsychotic Drugs Market is segmented based on Therapeutic Class, Drug Type, Distribution Channel, Application, and Geography.
  • By Therapeutic Class, the market is classified into First Generation, Second Generation, and Third Generation.
  • By Drug Type, the market is classified into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate, and Others.
  • By Distribution Channel, the market is classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
  • By Application, the market is classified into Bipolar Disorders, Dementia, Schizophrenia, and Unipolar Depression.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Alkermes PLC, AstraZeneca PLC, Eli Lilly and Co., Otsuka Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Pfizer, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Antipsychotic Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Antipsychotic Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Antipsychotic Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth Market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the Market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Prevalence of Psychosis and Associated Diseases
4.1.2 Rising Drug Approval from Governments
4.1.3 Growing Awareness Regarding Mental Health and Wellness
4.2 Restraints
4.2.1 Stringent Regulatory Framework and Compliance
4.3 Opportunities
4.3.1 R&D and Clinical Trials for New Antipsychotic Drugs
4.3.2 Improvements in Antipsychotic Drug Testing
4.4 Challenges
4.4.1 Side-effects of Antipsychotic Therapeutics
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 SWOT Analysis
5.5 Impact of COVID-19
5.6 Impact of Economic Slowdown & Impending Recession
5.7 Ansoff Matrix Analysis
6 Global Antipsychotic Drugs Market, By Drug Type
6.1 Introduction
6.2 Risperidone
6.3 Quetiapine
6.4 Olanzapine
6.5 Aripiprazole
6.6 Brexpiprazole
6.7 Paliperidone Palmitate
6.8 Others
7 Global Antipsychotic Drugs Market, By Therapeutic Class
7.1 Introduction
7.2 First Generation
7.3 Second Generation
7.4 Third Generation
8 Global Antipsychotic Drugs Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9 Global Antipsychotic Drugs Market, By Application
9.1 Introduction
9.2 Bipolar Disorders
9.3 Dementia
9.4 Schizophrenia
9.5 Unipolar Depression
10 Americas' Antipsychotic Drugs Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas
11 Europe's Antipsychotic Drugs Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Italy
11.9 Netherlands
11.10 Norway
11.11 Poland
11.12 Russia
11.13 Spain
11.14 Sweden
11.15 Switzerland
11.16 United Kingdom
11.17 Rest of Europe
12 Middle East and Africa's Antipsychotic Drugs Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Qatar
12.5 Saudi Arabia
12.6 South Africa
12.7 United Arab Emirates
12.8 Rest of MEA
13 APAC's Antipsychotic Drugs Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific
14 Competitive Landscape
14.1 Competitive Quadrant
14.2 Market Share Analysis
14.3 Strategic Initiatives
14.3.1 M&A and Investments
14.3.2 Partnerships and Collaborations
14.3.3 Product Developments and Improvements
15 Company Profiles
15.1 Alkermes PLC
15.2 Allergan PLC
15.3 AstraZeneca PLC
15.4 Bristol-Myers Squibb Co.
15.5 Daiichi Sankyo Co. Ltd.
15.6 Dr. Reddy's Laboratories
15.7 Eli Lilly and Co.
15.8 Flagship Biotech International Pvt. Ltd.
15.9 GlaxoSmithKline PLC
15.10 H. Lundbeck A/S
15.11 Hikma Pharmaceuticals PLC
15.12 Johnson & Johnson
15.13 Luye Pharma Group
15.14 Merck & Co. Inc.
15.15 Mylan N.V.
15.16 Otsuka Pharmaceutical Co. Ltd.
15.17 Pfizer, Inc.
15.18 Sumitomo Dainippon Pharma Co. Ltd.
15.19 Vanda Pharmaceuticals Inc.
16 Appendix
16.1 Questionnaire

Companies Mentioned

  • Alkermes PLC
  • Allergan PLC
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Co.
  • Flagship Biotech International Pvt. Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Luye Pharma Group
  • Merck & Co. Inc.
  • Mylan N.V.
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer, Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Vanda Pharmaceuticals Inc.

Table Information